Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Gerritsen

Showing results (201-210 of 224) with videos related to

Pageof 23
Sort By:
Clinical Genitourinary Cancer|March 13, 2025
Learning From Evidence: Changes in Real-World Use of Second Androgen Receptor Targeted Treatments in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Dianne Bosch, Kim J M van der Velden, Tom Belleman, et al.
Future Oncology (London, England)|May 30, 2020
Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancerMalou Cp Kuppen, Hans M Westgeest, Maarten J van der Doelen, et al.
Journal for Immunotherapy of Cancer|November 16, 2019
Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancerHarm Westdorp, Jeroen H A Creemers, Inge M van Oort, et al.
Drugs - Real World Outcomes|March 22, 2022
Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate CancerMarscha S Holleman, Simone A Huygens, Maiwenn J Al, et al.
The Lancet. Oncology|February 14, 2012
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialAlfons J M van den Eertwegh, Jurjen Versluis, H Pieter van den Berg, et al.
Prostate Cancer and Prostatic Diseases|August 12, 2024
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 studyJulie N Graff, Christopher J Hoimes, Winald R Gerritsen, et al.
European Urology Focus|May 5, 2020
Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer RegistryJessica C L Notohardjo, Malou C P Kuppen, Hans M Westgeest, et al.
BMC Cancer|September 15, 2020
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trialBastiaan M Privé, Marcel J R Janssen, Inge M van Oort, et al.
British Journal of Cancer|November 1, 2025
Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-studyIris S H Kloots, Peter H J Slootbeek, Sofie H Tolmeijer, et al.
The Lancet. Oncology|April 2, 2026
[<sup>177</sup>Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 studyBastiaan M Privé, Walter Noordzij, Constantijn H J Muselaers, et al.
Pageof 23

Showing results (201-210 of 224) with videos related to

Sort By:
Pageof 23
Clinical Genitourinary Cancer|March 13, 2025
Learning From Evidence: Changes in Real-World Use of Second Androgen Receptor Targeted Treatments in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Dianne Bosch, Kim J M van der Velden, Tom Belleman, et al.
Future Oncology (London, England)|May 30, 2020
Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancerMalou Cp Kuppen, Hans M Westgeest, Maarten J van der Doelen, et al.
Journal for Immunotherapy of Cancer|November 16, 2019
Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancerHarm Westdorp, Jeroen H A Creemers, Inge M van Oort, et al.
Drugs - Real World Outcomes|March 22, 2022
Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate CancerMarscha S Holleman, Simone A Huygens, Maiwenn J Al, et al.
The Lancet. Oncology|February 14, 2012
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialAlfons J M van den Eertwegh, Jurjen Versluis, H Pieter van den Berg, et al.
Prostate Cancer and Prostatic Diseases|August 12, 2024
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 studyJulie N Graff, Christopher J Hoimes, Winald R Gerritsen, et al.
European Urology Focus|May 5, 2020
Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer RegistryJessica C L Notohardjo, Malou C P Kuppen, Hans M Westgeest, et al.
BMC Cancer|September 15, 2020
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trialBastiaan M Privé, Marcel J R Janssen, Inge M van Oort, et al.
British Journal of Cancer|November 1, 2025
Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-studyIris S H Kloots, Peter H J Slootbeek, Sofie H Tolmeijer, et al.
The Lancet. Oncology|April 2, 2026
[<sup>177</sup>Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 studyBastiaan M Privé, Walter Noordzij, Constantijn H J Muselaers, et al.
Pageof 23